Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $161,600.00 in Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 40,000 shares of the stock in a transaction on Friday, June 14th. The stock was acquired at an average cost of $4.04 per share, for a total transaction of $161,600.00. Following the acquisition, the chief financial officer now directly owns 40,000 shares in the company, valued at $161,600. The transaction was disclosed in a filing with the SEC, which is available through this link.

Daron Evans also recently made the following trade(s):

• On Wednesday, May 29th, Daron Evans acquired 451 shares of Rezolute stock. The stock was acquired at an average cost of $3.50 per share, with a total value of $1,578.50.
• On Thursday, May 23rd, Daron Evans bought 58 shares of Rezolute stock. The shares were bought at an average cost of $2.85 per share, for a total transaction of $165.30.

Rezolute Stock Down 23.4 %

Shares of RZLT stock opened at $3.95 on Monday. The company has a market capitalization of $158.51 million, a P/E ratio of -3.46 and a beta of 1.31. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The firm has a 50-day moving average price of $3.45 and a 200 day moving average price of $2.09.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, May 15th. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). As a group, research analysts expect that Rezolute, Inc. will post -1.15 earnings per share for the current year.

Institutional Trading of Rezolute

Several large investors have recently made changes to their positions in the business. Federated Hermes Inc. lifted its position in Rezolute by 53.6% during the 4th quarter. Federated Hermes Inc. now owns 10,154,327 shares of the company’s stock worth $10,083,000 after buying an additional 3,544,053 shares in the last quarter. Vivo Capital LLC lifted its position in shares of Rezolute by 569.4% during the fourth quarter. Vivo Capital LLC now owns 3,242,842 shares of the company’s stock worth $3,219,000 after purchasing an additional 2,758,403 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of Rezolute during the first quarter valued at approximately $4,080,000. Vanguard Group Inc. grew its stake in shares of Rezolute by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after purchasing an additional 145,700 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in Rezolute in the 1st quarter worth approximately $510,000. Institutional investors own 82.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RZLT. JMP Securities restated a “market outperform” rating and issued a $7.00 price target on shares of Rezolute in a research report on Thursday, April 18th. Craig Hallum initiated coverage on Rezolute in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 target price on the stock. Jonestrading assumed coverage on Rezolute in a research note on Thursday, April 18th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Wednesday, May 22nd. Finally, Maxim Group began coverage on Rezolute in a report on Tuesday, April 9th. They set a “buy” rating and a $8.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $9.67.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.